Name: Possible-Worlds of the Absurdist Texts (en Inglés)
Price: 46.26 USD
Availability: InStock
Author: Saba Ajmal; Shumaila Bari
ISBN: 9783330024052

portada Possible-Worlds of the Absurdist Texts (en Inglés)

Formato

Libro Físico

Editorial

Lap Lambert Academic Publishing

Autor

Saba Ajmal; Shumaila Bari

Año

2016

Idioma

Inglés

N° páginas

Encuadernación

Tapa Blanda

ISBN13

9783330024052

N° edición

Possible-Worlds of the Absurdist Texts (en Inglés)

Saba Ajmal; Shumaila Bari (Autor) · Lap Lambert Academic Publishing · Tapa Blanda

Libro Nuevo

$ 46.26

$ 92.51

Ahorras: $ 46.26

50% descuento

Envío normal

Origen: España (Costos de importación incluídos en el precio)

Se enviará desde nuestra bodega entre el Martes 23 de Julio y el Jueves 01 de Agosto.

Lo recibirás en cualquier lugar de Ecuador entre 1 y 3 días hábiles luego del envío.

Reseña del libro "Possible-Worlds of the Absurdist Texts (en Inglés)"

The second edition of *Immunotherapy *is an updated overview of immuno-oncology in acute myleloid leukemia, non-small cell lung cancer and melanoma, showcasing advances in the management of cancer broadly classified as hematological malignancies and solid tumors. Though the spectrum of clinical activity and duration of response seen with these agents is promising, objective response is limited to a subset of patients and is often associated with distinct side effects that are potentially life-threatening. With increasing use of checkpoint inhibitors as standard of care and in clinical trials, the burden of immune-related adverse events will undoubtedly increase. Given these limitations and increase in health care costs associated with such therapies, it is essential to identify patients who are likely to respond to immunotherapy and those who are at a risk for developing treatment-related side effects.
This new edition will inform readers on the latest in biomarker development to identify patients who are more likely to respond, and strategies to overcome the challenges of immune-related adverse events. In addition, the authors recognize that including the missing patient voice in clinical trials and longitudinal assessment of symptom reports may help to identify early indicators of response or toxicity. Thus, the book includes a chapter on patient-reported outcomes in patients treated with immunotherapies. The authors believe that acquiring this knowledge will help health care professionals make informed treatment decisions.
Edited by two renowned experts in the field, the book’s chapters are written by a diverse cast of experts conducting cutting-edge research, providing the reader with the most up-to-date science.